NCT05177796 2024-10-24
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
8 trialsNCT03069950 2019-05-21
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT01634880 2016-05-23
Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies
The University of Texas Health Science Center at San Antonio
Phase 2 Withdrawn
NCT00984217 2016-01-08
Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies
University of Pittsburgh
Phase 2 Withdrawn
NCT01312493 2015-08-28
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01130701 2015-03-17
PMABIIS
University of Massachusetts, Worcester
Phase 2 Withdrawn
NCT01172717 2013-07-26
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Boston Medical Center
Phase 2 Withdrawn
NCT00346099 2008-01-07
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
NSABP Foundation Inc
Phase 2 Withdrawn